Collegium Pharmaceutical (COLL) Net Margin (2016 - 2026)

Collegium Pharmaceutical has reported Net Margin for 11 years, with the latest figure at 7.53% in Q2 2026.

• On a quarterly basis, Net Margin fell 1390.0% year-over-year to 7.53% in Q2 2026; TTM through Jun 2026 was 5.93%, a 80.0% increase from a year earlier, with the FY2025 full-year figure at 8.05%, down 290.0% from the prior year.
• Net Margin was 7.53% for Q2 2026 at Collegium Pharmaceutical, down from 7.49% in the prior quarter.
• The five-year high for Net Margin was 21.33% in Q4 2023, with the low at 15.6% in Q1 2022.
• Average Net Margin over 5 years is 4.77%, with a median of 6.63% recorded in 2024.
• The largest YoY upside for Net Margin was 8637 bps in 2022 against a maximum downside of 9343 bps in 2022.
• Over 5 years, Net Margin stood at 5.12% in 2022, then jumped by 517 bps to 21.33% in 2023, then sank by 68 bps to 6.89% in 2024, then grew by 20 bps to 8.26% in 2025, then plunged by 191 bps to 7.53% in 2026.
• The last three Net Margin figures came in at 7.53% (Q2 2026), 7.49% (Q1 2026), and 8.26% (Q4 2025), per Business Quant data.